CPHI 2025: we reaffirm our leading position in global health

Once again, we participated in CPHI 2025. The international pharmaceutical ingredients industry trade fair brought together global sector leaders in Frankfurt from October 28-30 to establish strategic contacts, present innovations, and consolidate business relationships.

Our presence at this essential event on the industry calendar served to reinforce our leading position in the development and manufacturing of APIs (active pharmaceutical ingredients) and functional ingredients derived from animal biomolecules.
 

CPHI: the strategic event for the pharmaceutical industry

Vanessa Villarreal, Strategic Marketing & Business Development Manager at Bioiberica, explained during the fair that CPHI "is the main event we have in the pharmaceutical ingredients industry. Here you can find the main leaders and establish a very broad and extensive network with all the people involved in the industry."

This assessment was shared by Oriol Huguet, Director of Business Development and Innovation Partnership, for whom "it is essential for Bioiberica, CPHI is really the place to be."

For a company with 50 years of experience in the development and production of pharmaceutical ingredients like ours, CPHI represents a unique opportunity to meet with established clients and potential partners.

As Joan Bassa, Director of Human Health, also noted, "50 years producing products would mean nothing if we didn't have customers who trust Bioiberica. It's a good opportunity to meet with them, review the year, focus on the next one, talk about forecasts and, ultimately, the best thing when you do business: having friends, and our customers are friends."

Solutions portfolio: from APIs to branded ingredients

During our participation in CPHI 2025, we presented the latest additions to our extensive portfolio, which reflects our specialization in the extraction, purification, and development of biomolecules of natural origin.
 

Consolidated APIs

Jaume Reguant, Director of Human Health, detailed the flagship products presented at the event: "The most important products we present are, obviously, heparin, which is our flagship product. We also present the rest of our APIs: chondroitin sulfate, glucosamine, and thyroid as API."

• Heparin, a world-reference anticoagulant, continues to be Bioiberica's flagship, consolidating its position as one of the main global producers of this essential active ingredient in the prevention and treatment of thrombosis.
• Chondroitin sulfate and glucosamine, glycosaminoglycans widely used in the treatment of joint conditions, represent another strategic line of the company, leveraging our expertise in the extraction of these bioactive molecules.
• Thyroid API completes our portfolio of pharmaceutical active ingredients, demonstrating Bioiberica's capacity to develop specialized therapeutic solutions from biological sources.
   

Branded functional ingredients

Beyond traditional APIs, we also presented the latest in our range of branded functional ingredients, which represent a differential added value in the market:

• Collavant: undenatured type II collagen, positioned for joint health applications with proprietary scientific evidence.
• Mobilee®: a high-quality hyaluronic acid matrix for mobility and joint health applications.
• Dermial: specialized ingredient for skin health and beauty, based on glycosaminoglycans rich in hyaluronic acid.
• DAOgest: innovative solution for digestive health, expanding the spectrum of applications of biomolecules developed by the company.

These branded ingredients reflect our strategy of offering not only purified molecules, but differentiated solutions with proprietary scientific backing and brand positioning.

A multidisciplinary approach: beyond commercial

A distinctive feature of Bioiberica's participation in CPHI was the presence of multidisciplinary teams that go beyond the traditional commercial profile, reflecting our commitment to technical and regulatory excellence.

Technical and scientific support

Javier Velasco, Director of R&D and Quality, justified his presence at the event: "It might seem strange to have an R&D manager here at the fair, but as a science-based company, we have to support the technical specifications of our products. Additionally, we are looking for partners for new developments. So it makes a lot of sense to be here from R&D."

This scientific approach allows clients and potential partners to directly access deep technical knowledge about the products, facilitating specialized discussions on specifications, analytical methods, manufacturing processes, and possibilities for joint development.

Regulatory expertise

Luisa Salazar, Head of Regulatory Affairs, highlighted another key dimension of Bioiberica's added value: "I am here at CPHI today to accompany our clients, help them understand the entire regulatory framework they must comply with to market either new ingredients or in new markets they want to access."

In an increasingly complex and demanding regulatory environment, especially in sectors such as pharmaceuticals and food supplements, having specialized regulatory support represents a significant competitive advantage for Bioiberica's clients.

Quality appreciation

Masami Sakota, Key Account Manager, shared the feedback received during the event: "It's a good opportunity to meet with our key customers. They really appreciate Bioiberica's high-quality products."

This quality assessment is the result of decades of investment in robust manufacturing processes, exhaustive quality control, and complete supply chain traceability, critical aspects when working with animal-derived ingredients intended for pharmaceutical applications.

New brand identity: "We Are All One"

One of the highlights of Bioiberica's participation in CPHI 2025 was the official presentation of our new corporate identity and branding strategy.

Adriana Olivares, Communications Director, explained that "this year at CPHI we are presenting our new branding, a new brand strategy. We just launched our new website in September, a month ago, and we are happy to show our customers and stakeholders our new tagline, 'We are all one', as well as our new purpose: for a healthier and safer world."

'Life Flows' campaign: science, innovation, and commitment

Complementing the new branding, we presented the "Life Flows" campaign, which conceptually connects with our flagship product, heparin, and its essential function in blood flow.

Marilyn Gonçalves, Global Product Marketing Manager, detailed the concept: "We are launching our new campaign, 'Life Flows'. It reminds us that the science, innovation, and commitment we have are directed toward something greater. It's directed toward the purpose of life."

This campaign transcends mere product promotion to position us as a company whose reason for being is deeply connected with improving people's quality of life and life expectancy.

Vision for the future: beyond heparin

Luis Solera, CEO of Bioiberica, shared the company's strategic vision for the coming years: "We really look forward to Bioiberica's future. Of course, it revolves around heparin, but also around other APIs we are developing. I think it's important for us to maximize the knowledge we have about animal biomolecules to be able to take other steps in the market."

Committed to innovation

Our participation in CPHI 2025 reflected the strength of a company with five decades of experience that is committed to continuous innovation, strategic expansion, and value generation for its clients and stakeholders.

The balance between consolidation of strengths (heparin, pharmaceutical quality, long-term relationships) and exploration of new opportunities (new APIs, branded ingredients, new markets) positions us favorably to face the challenges of a constantly evolving pharmaceutical market.

Our new brand identity "We are all one" and the corporate purpose of "For a healthier and safer world" provide a coherent conceptual framework that connects the company's daily activity with a broader positive impact on society.

As our CEO, Luis Solera, expressed, the future is built on maximizing the unique knowledge the company has accumulated about animal biomolecules, a strategic asset that will continue to generate opportunities in the coming years.